» Authors » Robert D Gibbons

Robert D Gibbons

Explore the profile of Robert D Gibbons including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 164
Citations 4381
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Saulsberry L, Jameson J, Gibbons R, Dolan M, Olopade O, ODonnell P
Clin Pharmacol Ther . 2025 Mar; PMID: 40033674
Tailoring pharmacogenomic (PGx) implementation to diverse populations is vital to promoting health equity. We assessed prescriptions for medications with potentially actionable PGx information to identify patient characteristics associated with differential...
2.
Cervantes P, Gibbons R, Seag D, Baroni A, Li A, Horwitz S
Evid Based Pract Child Adolesc Ment Health . 2025 Jan; 9(4):561-574. PMID: 39872043
While the emergency department (ED) is an important setting for identifying youth with psychiatric symptoms and connecting them to services, the demands of the ED make efficient and accurate measurement...
3.
Gibbons R, Lauderdale D, Wilson R, Bennett D, Arar T, Gallo D
Alzheimers Dement (N Y) . 2025 Jan; 10(4):e70018. PMID: 39748843
Introduction: Up to 20% of older adults in the United States have mild cognitive impairment (MCI), and about one-third of people with MCI are predicted to transition to Alzheimer's disease...
4.
Clementz B, Assaf M, Sweeney J, Gershon E, Keedy S, Hill S, et al.
Adv Neurobiol . 2024 Nov; 40:685-723. PMID: 39562461
Categorical diagnosis, a pillar of the medical model, has not worked well in psychiatry where most diagnoses are still exclusively symptom based. Uncertainty continues about whether categories or dimensions work...
5.
Bareis N, Olfson M, Dixon L, Chwastiak L, Monroe-DeVita M, Kessler R, et al.
J Affect Disord . 2024 Aug; 366:317-325. PMID: 39191309
Background: Knowledge of clinical, treatment and life circumstances of individuals with bipolar I disorder (BP-I) in US households is informed by decades old epidemiological surveys. Methods: The Mental and Substance...
6.
Gibbons R, Olfson M, Saulsberry L, Edlund M, Zangeneh S, Bareis N, et al.
JAMA Psychiatry . 2024 Jul; 81(10):976-984. PMID: 39046728
Importance: Community-level social vulnerability (SV) is associated with physical illness and premature mortality. Its association with mental health (MH) and substance use disorders (SUDs) needs further study. Objective: To study...
7.
Gibbons R, Ryan N, Tsui F, Harakal J, George-Milford B, Porta G, et al.
J Am Acad Child Adolesc Psychiatry . 2024 May; 64(3):398-405. PMID: 38782090
Objective: Suicide is a leading cause of death in adolescents and young adults and has increased substantially in the past 15 years. Accurate suicide risk stratification based on rapid screening...
8.
Gibbons R, Hur K, Lavigne J, Mann J
Psychiatry Res . 2024 Mar; 335:115857. PMID: 38493738
Background: From 2000-2021, U.S. suicide deaths have risen 36 %. Identification of pharmacological agents associated with increased suicide risk and safer alternatives may help reduce this trend. Methods: An exposure-only...
9.
Adams Z, Hulvershorn L, Smoker M, Marriott B, Aalsma M, Gibbons R
Subst Use Misuse . 2024 Jan; 59(6):867-873. PMID: 38270342
Purpose: Computerized adaptive tests (CATs) are highly efficient assessment tools that couple low patient and clinician time burden with high diagnostic accuracy. A CAT for substance use disorders (CAT-SUD-E) has...
10.
Clementz B, Chattopadhyay I, Trotti R, Parker D, Gershon E, Hill S, et al.
Schizophr Res . 2023 Sep; 260:143-151. PMID: 37657281
Clinically defined psychosis diagnoses are neurobiologically heterogeneous. The B-SNIP consortium identified and validated more neurobiologically homogeneous psychosis Biotypes using an extensive battery of neurocognitive and psychophysiological laboratory measures. However, typically...